Can you import tirzepatide into the UK?

Tirzepatide, sold in the UK under the brand Mounjaro, is a licensed prescription-only medicine, and that single fact reshapes the personal-import question that people keep asking about tirzepatide. The UK medicines-licensing rules do contain an exemption for a person importing a medicine for their own use^[3], the same carve-out that comes up for grey-market peptides. But tirzepatide is not a grey-market peptide. It is an authorised medicine that can only be obtained with a prescription^[1], so the import exemption answers a much narrower question than the vendors selling to UK addresses would like you to think.

This page describes the law and the enforcement pattern. It is not a route map for buying tirzepatide without a prescription, and it is not medical advice. The tirzepatide peptide page covers the clinical evidence, the UK regulation hub covers the wider picture, and if you are weighing a decision, that conversation belongs with a clinician and, on the legal side, a solicitor.

What tirzepatide's UK status actually is

The MHRA authorised Mounjaro for weight management in adults on 8 November 2023, through a national application route, adding to its existing licence for type-2 diabetes^[2]. In the EU and EEA the same product is centrally authorised through the EMA, with Eli Lilly Nederland B.V. as the marketing-authorisation holder, and the EMA is explicit that Mounjaro "can only be obtained with a prescription"^[1]. So this is not a compound sitting in a regulatory gap. It is a medicine with a marketing authorisation and a prescription-only classification.

That classification is the whole game. For an unauthorised peptide, the argument is about whether the compound counts as a medicine at all. For tirzepatide there is no such argument. The lawful way to get it on the NHS runs through the NICE technology appraisals, which we cover in our explainer on UK NICE access, and the lawful private route runs through a prescriber and a registered pharmacy. Both routes start with a prescription. There is no consumer version of the process that skips it.

The personal-import exemption, and what it does not do

Regulation 17(1) of the Human Medicines Regulations 2012 says a person may not import a medicinal product into Great Britain except in accordance with a licence. Regulation 17(6) then removes personal imports from that requirement: it "does not apply to a person who imports a medicinal product for administration to himself or herself or to any other person who is a member of that person's household"^[3]. This is the passage forum posts point to when they say personal import is legal. It is real, and it is narrow.

What regulation 17(6) removes is the manufacturer's-licence requirement for the act of importing. What it does not touch is regulation 214, which says a person "may not sell or supply a prescription only medicine except in accordance with a prescription given by an appropriate practitioner"^[4]. Tirzepatide is a prescription-only medicine, so the sale into your hands still needs a prescription behind it. The import exemption does not convert a prescription-only medicine into something you can lawfully buy over a website. It removes one licensing hurdle on your side and leaves the supply-side rules fully intact.

The MHRA's own guidance on importing a human medicine makes the point from the other direction. It is written for wholesalers and manufacturers, requiring a wholesale-distribution or manufacturer's licence, and for an unlicensed medicine it requires the importer to notify the MHRA of the intent to import before doing so, with the import allowed to proceed only "if the MHRA does not object to it"^[6]. There is no parallel consumer scheme, because the consumer route for a prescription-only medicine is a prescription.

What you are actually buying on the grey market

A website shipping tirzepatide to a UK address without a prescription is selling one of two things, and neither is lawful for it to sell. The first is falsified branded product: fake Mounjaro pens made to look like the real thing. The second is unlicensed "research-use only" tirzepatide in vials, which is an unauthorised medicinal product. Regulation 46 is blunt about that second category: "A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product"^[5], a product being unauthorised when no UK marketing authorisation or equivalent is in force for it.

This is not a hypothetical supply chain. In October 2025 the MHRA dismantled an illicit manufacturing site near Northampton and seized more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch to customers, alongside tens of thousands of empty pens ready to be filled, with the finished products valued at more than a quarter of a million pounds^[7]. The pens being sold as tirzepatide are, in a growing share of cases, made by criminal networks with no batch release, no pharmacopoeial identity testing and no way for a buyer to know what is in the vial.

What customs flags

Regulation 17(6) exempts you from a licensing requirement. It does not oblige Border Force to wave the parcel through. The MHRA works with Border Force on medicines interception at the UK border, and unlicensed weight-loss injections have become one of the headline targets: the agency's Criminal Enforcement Unit has run repeated seizures of tirzepatide and retatrutide pens through 2025 and into 2026^[7]. For a personal parcel the realistic outcome is a seizure and a letter rather than a prosecution, because the enforcement effort concentrates on the supply side where regulations 46 and 214 give the MHRA something to charge.

The practical consequences follow from that. If the parcel is intercepted, you have lost the money, and because the transaction was unlawful at the seller's end there is no consumer-protection route to recover it. If it is not intercepted, you are left holding a vial from a supplier operating outside medicines law. The MHRA's advice around its seizures is consistent: prescription medicines should only be obtained from a registered pharmacy, and buying from unregulated sources "carries serious risks to your health"^[7].

The grey-market reality, without the endorsement

We do not recommend vendors for prescription-only medicines, and we are not going to point anyone at a non-prescription import route. The honest supply picture is that the market for cheap tirzepatide outside the pharmacy system is now substantially a counterfeit market, run by people manufacturing pens in unregulated conditions and labelling them as a drug that in legitimate supply comes with batch traceability and an adverse-event reporting route. What that removes is documented in the safety section of the tirzepatide page. The saving over a private prescription is the cost of removing every one of those safeguards.

None of this is unique to tirzepatide. The same supply-side rules catch any prescription-only or unauthorised medicine sold to UK consumers, including its sibling GLP-1 drug semaglutide, which is why the regulation sections of our peptide pages read similarly across compounds. What is specific to tirzepatide is that a fully lawful route exists: it is a licensed medicine, and a prescriber can assess whether it is appropriate for you. The regulation section of the tirzepatide page tracks how the status differs across the other countries we cover.

Where this lands

For a UK reader the picture is narrower than the "personal import is legal" headline suggests. Importing a medicine for your own use sits inside a genuine statutory exemption from the licensing rule. Buying a prescription-only medicine without a prescription does not, and the overseas sale into your hands is unlawful at the seller's end whether or not the exemption covers your import. The safe and lawful way to get tirzepatide in the UK is through a prescriber and a registered pharmacy, on the NHS or privately, and the decision about whether it is right for you belongs with a clinician who knows your history. See our NICE access explainer for the NHS routes.

Regulations change, and enforcement priorities change faster. Verify the current text of the Human Medicines Regulations 2012 on legislation.gov.uk before relying on any of the above, and use our UK regulation hub to track the status across the jurisdictions we cover.